Skip to main content

Value Stock - Dividend - Research Selection

ISIN: , WKN:

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical Officer

2022-11-15
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that Linda Neuman, M.D., M.B.A. has been appointed chief medical officer. Dr. Neuman's appointment is an internal promotion from her previous role as Aeglea's senior vice president of clinical development.

Aeglea BioTherapeutics appoints Linda Neuman as Chief Medical Officer

2022-11-15
Aeglea BioTherapeutics an... AGLE

Best Penny Stocks To Buy Now That CPI Is Out? 4 To Watch Before Next Week

2022-11-10
Hot penny stocks to watch after October's CPI report.

H.C. Wainwright Sticks to Its Hold Rating for Aeglea Biotherapeutics (AGLE)

2022-11-04
In a report released today, Edward White from H.C. Wainwright reiterated a Hold rating on Aeglea Biotherapeutics (AGLE – Research Report), with a price target...

Aeglea Biotherapeutics (AGLE) Reports Q3 Loss, Misses Revenue Estimates

2022-11-03
Aeglea (AGLE) delivered earnings and revenue surprises of 20.83% and 72.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates

2022-11-03
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the third quarter ended September 30, 2022 and provided program updates.

Aeglea: Q3 Earnings Snapshot

2022-11-03
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Aeglea BioTherapeutics reports Q3 EPS (19c), consensus (23c)

2022-11-03
As of September 30, 2022,... AGLE

4 Penny Stocks To Buy According To Analysts Right Now

2022-11-01
Penny stocks with bullish analyst ratings. Time to buy or avoid entirely?

Why Are Penny Stocks Volatile? 3 Reasons and How to Profit 

2022-10-29
This is why penny stocks are so volati